Please assess the completion status of the following clinical trial:

Trial Title: Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18-65, inclusive~* Diagnosis of NMO using Wingerchuk 2006 NMO Criteria~* EDSS 0-6.5~* Treatment with a minimum of one NMO therapy in past 12 months~* One objective and documented relapse in the past 12 months and two relapse events in the past 24 months despite medical therapy~* ECOG performance status 0-3~* Platelets ≥100 x 109/L~* ALT ≤3 x ULN~* Total bilirubin ≤2.0 x ULN, except in patients with Gilbert syndrome or in patients in whom the bilirubin rise is of non-hepatic origin~* Serum creatinine \<1.5 x ULN or creatinine clearance ≥50 cc/min~* Patients must reside in Alberta, Canada for the duration of the transplant period of the trial~Exclusion Criteria:~* Any illness that would jeopardize the ability of the patient to complete study protocol~* Prior malignancy unless non-melanoma skin cancer, carcinoma in-situ of the cervix (CIN) or breast, or malignancy treated more than 5 years previously with no evidence of recurrent disease since initial treatment~* Pregnant or lactating females. Women of childbearing potential must have a negative serum or urine β-hCG pregnancy test at screening~* Inability or unwillingness to pursue effective means of birth control~* FEV1/FVC \< 50% of predicted~* DLCO \< 50% of predicted~* Resting LVEF \< 50 %~* Known hypersensitivity to mouse, rabbit, or E. Coli derived proteins, or to iron compounds/medications~* Presence of metallic objects implanted in the body that would preclude the ability of the patient to safely have MRI exams~* Unable or unwilling to provide written informed consent for participation~* Active infection except asymptomatic bacteriuria~* Any use of investigational therapies within 4 weeks prior to initiation of study treatment~* Patients dependent on prednisone who cannot be successfully tapered to a maximum of 0.5mg/kg/d prior to mobilization therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AHSCT (Type: EXPERIMENTAL): All patients undergo autologous hematopoietic stem cell transplantation in a two stage process.

Based on this trial design, predict the completion outcome and termination type (if applicable).